Sean Glynn, Noble on Why an 88% Adoption Rate Proves “Adherence” Was the Wrong Word

Sean Glynn leads patient engagement and evidence programs at Noble, a division of Aptar Pharma. Sean joins Jim Joyce and Eugene to unpack why he thinks medication adherence still isn't solved, and why he'd retire the word "adherence" altogether. His team's SureStart Rx program moved injection training out of doctors' offices and into specialty pharmacy workflows, and the pilot data holds up: 88% patient usage, first doses 3.5 days sooner, and one to two extra doses over six months. Sean also traces the winding path that got him here: organizational behavior grad school, a house-flipping business, pharmacoeconomics at the University of Florida, Health Beacon, and ZS Associates. 00:00 - Cold Open - The Dose Is the Poison02:00 - Meet Sean Glynn - Noble, Aptar, and a Decades-Long Friendship04:00 - Irish Roots and the Family That Reverse-Immigrated Twice09:00 - Delicate Hands to Org Behavior - Finding the Thing13:00 - The Metric Pharma Got Wrong - Commitment Beats Satisfaction18:00 - The Construction Detour, and How Health Beacon Started23:00 - ZS Associates, WHOOP, and the Integrated Evidence Plans26:00 - Dying on the Vine - Why Evidence Plans Get Skipped30:00 - The Noble Pivot - SureStart Rx and the Distribution Problem35:00 - Becoming an Intrapreneur Inside a 9-Billion-Dollar Company38:00 - Why Injections Are Still Genuinely Hard40:00 - The Ozempic Story, Cold Plunges, and Ronaldo's Free Kick44:00 - Killing the Word "Adherence"48:00 - Where Noble Goes Next - AI, Sensors, and Global Expansion50:00 - Closing Question - Advice to His Younger Self Guest: Sean Glynn, Noble / Aptar Pharma - LinkedIn | Noble | Aptar Pharma Mentioned in this episode: Sean McDade and PeopleMetrics, Craig Baker and Jeff Baker (Noble's founders), BioPlus Specialty Pharmacy, WHOOP, ZS Associates, Health Beacon, University of Florida. If you enjoyed this episode, subscribe and leave a review - it's the easiest way to help more people find the show.